{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:09:22Z","timestamp":1789729762639,"version":"4.0.1"},"reference-count":65,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3597,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>When benzodiazepines (BZs) supplanted barbiturates as a favored, safer treatment for anxiety and sleep disorders in the 1960s, the abuse liability and dependence potential of these drugs were little understood. Widespread recognition of the difficulty of stopping use of chronically taken BZs emerged through the popular press in the late 1970s, which resulted in reluctance to prescribe these otherwise clinically useful compounds. Evolution of the understanding of the biochemical basis for BZ effects in the 1980s and 1990s, coupled with regulatory emphasis on collection of data used in legal scheduling decisions, made possible a targeted search for drugs that would provide effective treatment for anxiety disorders in the absence of abuse liability or dependence potential. Compounds that have selective efficacy at subtypes of the \u03b3-aminobutyric acid type A receptor, are active in preclinical anxiolytic screens, but negative in preclinical studies of behavior relevant to evaluation of abuse liability appear to be one promising means for achieving this end.<\/jats:p>","DOI":"10.1017\/s1092852900009883","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:41:59Z","timestamp":1470112919000},"page":"31-39","source":"Crossref","is-referenced-by-count":50,"title":["Contributions of GABA<sub>A<\/sub>Receptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders"],"prefix":"10.1017","volume":"10","author":[{"given":"Nancy A.","family":"Ator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900009883_ref062","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051030"},{"key":"S1092852900009883_ref055","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199612000-00010"},{"key":"S1092852900009883_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1950.02310250007001"},{"key":"S1092852900009883_ref041","first-page":"299","volume-title":"Benzodiazepine dependence. ISI Atlas of Science: Pharmacology","author":"Lader","year":"1987"},{"key":"S1092852900009883_ref044","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244196"},{"key":"S1092852900009883_ref018","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900009871"},{"key":"S1092852900009883_ref020","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429621"},{"key":"S1092852900009883_ref051","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00122-8"},{"key":"S1092852900009883_ref025","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00102-9"},{"key":"S1092852900009883_ref034","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(81)90246-7"},{"key":"S1092852900009883_ref049","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432169"},{"key":"S1092852900009883_ref061","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-3565(25)23193-7","article-title":"Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability","volume":"255","author":"Evans","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref028","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.8.3.294"},{"key":"S1092852900009883_ref052","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(91)90049-B"},{"key":"S1092852900009883_ref005","volume-title":"I'm Dancing as Fast as I Can","author":"Gordon","year":"1979"},{"key":"S1092852900009883_ref031","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199102000-00002"},{"key":"S1092852900009883_ref023","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00097-8"},{"key":"S1092852900009883_ref059","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00098-X"},{"key":"S1092852900009883_ref001","first-page":"345","volume-title":"The Pharmacological Basis of Therapeutics","author":"Rall","year":"1990"},{"key":"S1092852900009883_ref021","unstructured":"World Health Organization. Guideline for the WHO review of dependence producing psychoactive substances for international control. Available at: http:\/\/www.who.int\/medicines\/library\/qsm\/who-edm-qsm-2000-5\/who-edm-qsm-000-5.shtml. Accessed on December 12, 2004."},{"key":"S1092852900009883_ref058","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/23.8.1h"},{"key":"S1092852900009883_ref048","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00123-X"},{"key":"S1092852900009883_ref035","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90351-1"},{"key":"S1092852900009883_ref011","doi-asserted-by":"publisher","DOI":"10.1038\/266732a0"},{"key":"S1092852900009883_ref004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-3565(25)27159-2","article-title":"The rapid development of physical dependence on barbiturates","volume":"150","author":"Jaffe","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)20029-5","article-title":"Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H] flunitrazepam and the omega 1 selective ligand [3H]zolpidem","volume":"247","author":"Denis","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-3565(24)37370-7","article-title":"Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons","volume":"285","author":"Weerts","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref016","doi-asserted-by":"publisher","DOI":"10.1177\/026988119801200405"},{"key":"S1092852900009883_ref033","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0022-3565(24)38290-4","article-title":"Drug discrimination analysis of partial agonists at the benzodiazepine site. I. Differential effects of U-78875 across training conditions in baboons and rats","volume":"289","author":"Ator","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref015","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040020-00008"},{"key":"S1092852900009883_ref006","unstructured":"Use and misuse of benzodiazepines. Hearing before the Subcommittee on Health and Scientific Research of the Committee on Labor and Human Resources, United States Senate, 96th Congress 1979; 1."},{"key":"S1092852900009883_ref057","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200009000-00008"},{"key":"S1092852900009883_ref030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-3565(25)22601-5","article-title":"Discriminative stimulus properties of buspirone in the pigeon","volume":"240","author":"Mansbach","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref036","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90534-6"},{"key":"S1092852900009883_ref065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-3565(25)24866-2","article-title":"Discriminative stimulus effects of atypical anxiolytics in baboons and rats","volume":"237","author":"Ator","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref009","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(88)90105-2"},{"key":"S1092852900009883_ref008","volume-title":"Depression and Anxiety","author":"Schwartz","year":"2003"},{"key":"S1092852900009883_ref024","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00096-6"},{"key":"S1092852900009883_ref002","first-page":"77","article-title":"Withdrawal effects of sodium amytal","volume":"12","author":"Alexander","year":"1951","journal-title":"Dis Nerv Syst"},{"key":"S1092852900009883_ref007","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900009901"},{"key":"S1092852900009883_ref038","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(90)90077-R"},{"key":"S1092852900009883_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(83)90385-4"},{"key":"S1092852900009883_ref064","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6769(199911\/12)25:3<139::AID-NRC3>3.0.CO;2-W"},{"key":"S1092852900009883_ref017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.1997.tb00324.x"},{"key":"S1092852900009883_ref022","volume-title":"Thirty-Second Report","year":"2001"},{"key":"S1092852900009883_ref019","doi-asserted-by":"publisher","DOI":"10.1038\/75761"},{"key":"S1092852900009883_ref042","first-page":"58","volume-title":"Benzodiazepine Dependence","author":"Higgit","year":"1993"},{"key":"S1092852900009883_ref053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0022-3565(25)10339-X","article-title":"Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic Zolpidem","volume":"263","author":"Perrault","year":"1992","journal-title":"Pharmacol Exp Ther"},{"key":"S1092852900009883_ref045","first-page":"34","article-title":"Intravenous buspirone self-administration in rhesus monkeys","volume":"43","author":"Balster","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"S1092852900009883_ref040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3565(25)28496-8","article-title":"Development of tolerance to and physical dependence on barbiturates in rhesus monkeys","volume":"172","author":"Yanagita","year":"1970","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref026","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00099-1"},{"key":"S1092852900009883_ref054","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91522-N"},{"key":"S1092852900009883_ref010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/j.1552-4604.1998.tb00009.x","article-title":"Problems and opportunities in regulation of benzodiazepines","volume":"38","author":"Woods","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"S1092852900009883_ref037","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0031-6997(25)06658-X","article-title":"Abuse liability of benzodiazepines","volume":"39","author":"Woods","year":"1987","journal-title":"Pharmacol Rev"},{"key":"S1092852900009883_ref039","doi-asserted-by":"publisher","DOI":"10.1126\/science.6287579"},{"key":"S1092852900009883_ref060","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-3565(25)32353-0","article-title":"Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo","volume":"215","author":"Griffiths","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref027","first-page":"101","volume-title":"Animal Research and Human Health","author":"Rush","year":"2001"},{"key":"S1092852900009883_ref047","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-3565(25)11429-8","article-title":"Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal","volume":"260","author":"Griffiths","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref032","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S0022-3565(24)36923-X","article-title":"Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative\/anxiolytics","volume":"282","author":"Ator","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900009883_ref046","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199104000-00006"},{"key":"S1092852900009883_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90012-Z"},{"key":"S1092852900009883_ref063","first-page":"164","volume-title":"Problems of Drug Dependence, 1982; Proceedings of the 44th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph Series 43","author":"Yanagita","year":"1983"},{"key":"S1092852900009883_ref050","volume-title":"Drug Alcohol Depend","author":"Ator"},{"key":"S1092852900009883_ref056","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979492"},{"key":"S1092852900009883_ref012","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(79)90341-1"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900009883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:57:35Z","timestamp":1749034655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900009883\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S1092852900009883"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900009883","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}